Brii Bio Adds 107,000 Shares to Treasury via HK$0.09 Million On-Market Buyback

Bulletin Express10-12

Brii Biosciences Limited (Brii Bio) disclosed that it repurchased 107,000 ordinary shares on 12 October 2026 through on-market transactions on the Hong Kong Stock Exchange.

The shares were bought at prices ranging from HK$0.84 to HK$0.865, translating into a volume-weighted average cost of HK$0.8523 per share and an aggregate outlay of HK$0.09 million.

Following the transaction: • Issued shares outstanding (excluding treasury shares) fell slightly to 722.06 million, down 0.0148%. • Treasury shares increased to 13.26 million, while total issued shares remained unchanged at 735.32 million.

The buyback formed part of the mandate approved on 16 June 2026, which authorises Brii Bio to repurchase up to 72.19 million shares. Cumulative purchases under this authority now stand at 538,000 shares, representing 0.0745% of the company’s issued share capital on the mandate date.

In accordance with Hong Kong Listing Rules, Brii Bio is subject to a 30-day moratorium—lasting until 11 November 2026—on issuing new shares or disposing of treasury shares following the latest repurchase.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment